Does the media prefer ADUS or FLGT?

In the previous week, Fulgent Genetics had 5 more articles in the media than Addus HomeCare. MarketBeat recorded 11 mentions for Fulgent Genetics and 6 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat Fulgent Genetics' score of -0.25 indicating that Addus HomeCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, FLGT or HTFL?

Fulgent Genetics has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fulgent Genetics $322.67M 1.52 -$60.51M -$2.82 N/A Heartflow $176.03M 12.91 -$116.79M -$3.11 N/A

Does the media refer more to FLGT or HTFL?

In the previous week, Fulgent Genetics had 4 more articles in the media than Heartflow. MarketBeat recorded 11 mentions for Fulgent Genetics and 7 mentions for Heartflow. Heartflow's average media sentiment score of 1.13 beat Fulgent Genetics' score of -0.25 indicating that Heartflow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Heartflow 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVAH or FLGT?

In the previous week, Fulgent Genetics had 8 more articles in the media than Aveanna Healthcare. MarketBeat recorded 11 mentions for Fulgent Genetics and 3 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 1.32 beat Fulgent Genetics' score of -0.25 indicating that Aveanna Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aveanna Healthcare 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor FLGT or SNDA?

In the previous week, Fulgent Genetics had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 11 mentions for Fulgent Genetics and 9 mentions for Sonida Senior Living. Sonida Senior Living's average media sentiment score of 0.98 beat Fulgent Genetics' score of -0.25 indicating that Sonida Senior Living is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Sonida Senior Living 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SGRY or FLGT?

In the previous week, Fulgent Genetics had 4 more articles in the media than Surgery Partners. MarketBeat recorded 11 mentions for Fulgent Genetics and 7 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.45 beat Fulgent Genetics' score of -0.25 indicating that Surgery Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surgery Partners 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Fulgent Genetics (FLGT) Competitors

$17.32 +0.77 (+4.63%)

As of 10:53 AM Eastern

Compare

FLGT vs. ADUS, HTFL, AVAH, SNDA, and SGRY

Should you buy Fulgent Genetics stock or one of its competitors? MarketBeat compares Fulgent Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulgent Genetics include Addus HomeCare (ADUS), Heartflow (HTFL), Aveanna Healthcare (AVAH), Sonida Senior Living (SNDA), and Surgery Partners (SGRY).

How does Fulgent Genetics compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.52	$95.91M	$5.41	21.43
Fulgent Genetics	$322.67M	1.52	-$60.51M	-$2.82	N/A

Addus HomeCare presently has a consensus price target of $131.50, suggesting a potential upside of 13.42%. Fulgent Genetics has a consensus price target of $27.00, suggesting a potential upside of 55.92%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Fulgent Genetics had 5 more articles in the media than Addus HomeCare. MarketBeat recorded 11 mentions for Fulgent Genetics and 6 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat Fulgent Genetics' score of -0.25 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Addus HomeCare has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Addus HomeCare has a net margin of 6.89% compared to Fulgent Genetics' net margin of -26.05%. Addus HomeCare's return on equity of 9.80% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 4.1% of Addus HomeCare shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Addus HomeCare beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Heartflow?

Fulgent Genetics (NASDAQ:FLGT) and Heartflow (NASDAQ:HTFL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Fulgent Genetics had 4 more articles in the media than Heartflow. MarketBeat recorded 11 mentions for Fulgent Genetics and 7 mentions for Heartflow. Heartflow's average media sentiment score of 1.13 beat Fulgent Genetics' score of -0.25 indicating that Heartflow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Heartflow	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics presently has a consensus target price of $27.00, indicating a potential upside of 55.92%. Heartflow has a consensus target price of $36.57, indicating a potential upside of 38.79%. Given Fulgent Genetics' higher probable upside, research analysts plainly believe Fulgent Genetics is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Fulgent Genetics has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.52	-$60.51M	-$2.82	N/A
Heartflow	$176.03M	12.91	-$116.79M	-$3.11	N/A

Fulgent Genetics has a net margin of -26.05% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Heartflow	-58.42%	N/A	-20.02%

48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 7.7% of Heartflow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Heartflow on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Aveanna Healthcare?

Aveanna Healthcare (NASDAQ:AVAH) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Aveanna Healthcare currently has a consensus target price of $10.78, suggesting a potential upside of 11.51%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 55.92%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Fulgent Genetics had 8 more articles in the media than Aveanna Healthcare. MarketBeat recorded 11 mentions for Fulgent Genetics and 3 mentions for Aveanna Healthcare. Aveanna Healthcare's average media sentiment score of 1.32 beat Fulgent Genetics' score of -0.25 indicating that Aveanna Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aveanna Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

88.0% of Aveanna Healthcare shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 5.3% of Aveanna Healthcare shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aveanna Healthcare has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Aveanna Healthcare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aveanna Healthcare	$2.52B	0.83	$225.03M	$1.18	8.19
Fulgent Genetics	$322.67M	1.52	-$60.51M	-$2.82	N/A

Aveanna Healthcare has a net margin of 10.37% compared to Fulgent Genetics' net margin of -26.05%. Aveanna Healthcare's return on equity of 124.68% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aveanna Healthcare	10.37%	124.68%	7.07%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Aveanna Healthcare beats Fulgent Genetics on 13 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Sonida Senior Living?

Fulgent Genetics (NASDAQ:FLGT) and Sonida Senior Living (NYSE:SNDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Fulgent Genetics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Sonida Senior Living has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Fulgent Genetics has higher earnings, but lower revenue than Sonida Senior Living. Sonida Senior Living is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.52	-$60.51M	-$2.82	N/A
Sonida Senior Living	$381.14M	5.06	-$70.78M	-$5.83	N/A

Fulgent Genetics currently has a consensus price target of $27.00, indicating a potential upside of 55.92%. Sonida Senior Living has a consensus price target of $43.00, indicating a potential upside of 5.54%. Given Fulgent Genetics' higher possible upside, equities research analysts clearly believe Fulgent Genetics is more favorable than Sonida Senior Living.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sonida Senior Living	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 87.6% of Sonida Senior Living shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 39.3% of Sonida Senior Living shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sonida Senior Living has a net margin of -24.15% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat Sonida Senior Living's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Sonida Senior Living	-24.15%	-36.98%	-7.08%

In the previous week, Fulgent Genetics had 2 more articles in the media than Sonida Senior Living. MarketBeat recorded 11 mentions for Fulgent Genetics and 9 mentions for Sonida Senior Living. Sonida Senior Living's average media sentiment score of 0.98 beat Fulgent Genetics' score of -0.25 indicating that Sonida Senior Living is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sonida Senior Living	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulgent Genetics and Sonida Senior Living tied by winning 8 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

48.1% of Fulgent Genetics shares are owned by institutional investors. 2.0% of Surgery Partners shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Surgery Partners has a net margin of -2.28% compared to Fulgent Genetics' net margin of -26.05%. Surgery Partners' return on equity of 1.04% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Surgery Partners has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

In the previous week, Fulgent Genetics had 4 more articles in the media than Surgery Partners. MarketBeat recorded 11 mentions for Fulgent Genetics and 7 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.45 beat Fulgent Genetics' score of -0.25 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Fulgent Genetics has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.63	-$77.90M	-$0.60	N/A
Fulgent Genetics	$322.67M	1.52	-$60.51M	-$2.82	N/A

Surgery Partners currently has a consensus target price of $21.60, indicating a potential upside of 36.45%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 55.92%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Surgery Partners beats Fulgent Genetics on 10 of the 17 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$492.74M	$9.93B	$6.81B	$12.55B
Dividend Yield	N/A	2.52%	2.59%	10.03%
P/E Ratio	-6.15	25.64	282.12	24.83
Price / Sales	1.52	4.72	573.08	78.59
Price / Cash	N/A	26.24	28.60	46.71
Price / Book	0.48	5.21	11.02	6.15
Net Income	-$60.51M	$311.05M	$3.49B	$347.61M
7 Day Performance	-11.56%	-0.28%	0.47%	1.17%
1 Month Performance	-16.94%	-0.95%	-4.24%	-3.46%
1 Year Performance	-6.55%	27.28%	62.63%	19.43%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	2.148 of 5 stars	$17.32 +4.6%	$27.00 +55.9%	-10.7%	$492.74M	$322.67M	N/A	1,315	Earnings Report
ADUS Addus HomeCare	3.0894 of 5 stars	$119.22 +3.1%	$131.50 +10.3%	+10.0%	$2.23B	$1.42B	22.04	50,659	Positive News
HTFL Heartflow	3.2565 of 5 stars	$25.59 +0.9%	$37.00 +44.6%	N/A	$2.21B	$191.42M	N/A	699	News Coverage Positive News Analyst Upgrade
AVAH Aveanna Healthcare	4.5447 of 5 stars	$9.89 +2.3%	$10.78 +9.0%	+151.1%	$2.15B	$2.52B	8.38	35,500	Positive News
SNDA Sonida Senior Living	2.0737 of 5 stars	$43.19 +0.9%	$43.00 -0.4%	N/A	$2.05B	$411.85M	N/A	5,140	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. ADUS, HTFL, AVAH, SNDA, and SGRY

How does Fulgent Genetics compare to Addus HomeCare?

Summary

How does Fulgent Genetics compare to Heartflow?

Summary

How does Fulgent Genetics compare to Aveanna Healthcare?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. ADUS, HTFL, AVAH, SNDA, and SGRY

How does Fulgent Genetics compare to Addus HomeCare?

Which has higher valuation and earnings, ADUS or FLGT?

Do analysts rate ADUS or FLGT?

Does the media prefer ADUS or FLGT?

Which has more risk and volatility, ADUS or FLGT?

Is ADUS or FLGT more profitable?

Do institutionals & insiders have more ownership in ADUS or FLGT?

Summary

How does Fulgent Genetics compare to Heartflow?

Does the media refer more to FLGT or HTFL?

Do analysts recommend FLGT or HTFL?

Which has better earnings & valuation, FLGT or HTFL?

Is FLGT or HTFL more profitable?

Do institutionals & insiders believe in FLGT or HTFL?

Summary

How does Fulgent Genetics compare to Aveanna Healthcare?

Do analysts rate AVAH or FLGT?

Does the media prefer AVAH or FLGT?

Do insiders and institutionals hold more shares of AVAH or FLGT?

Which has more risk and volatility, AVAH or FLGT?

Which has preferable valuation & earnings, AVAH or FLGT?

Is AVAH or FLGT more profitable?

Summary

How does Fulgent Genetics compare to Sonida Senior Living?

Which has more volatility and risk, FLGT or SNDA?

Which has preferable earnings & valuation, FLGT or SNDA?

Do analysts prefer FLGT or SNDA?

Do institutionals and insiders have more ownership in FLGT or SNDA?

Is FLGT or SNDA more profitable?

Does the media favor FLGT or SNDA?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Do insiders & institutionals believe in SGRY or FLGT?

Is SGRY or FLGT more profitable?

Which has more risk & volatility, SGRY or FLGT?

Does the media refer more to SGRY or FLGT?

Which has higher earnings and valuation, SGRY or FLGT?

Do analysts rate SGRY or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools